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Background: Sunitinib, a tyrosine kinase inhibitor currently in use for the treatment of metastatic renal cell
carcinoma (mRCC), has been reported to modulate immunosuppressive cells such as myeloid-derived suppressor
cells (MDSCs) and regulatory T cells (Tregs) in addition to exerting anti-angiogenic effects. We conducted a clinical
trial of dendritic cell (DC)-based immunotherapy together with sunitinib in mRCC patients in an effort to enhance
immunotherapeutic efficacy by inhibiting immunosuppressive cells.
Methods: Patients aged ≥20 years with advanced or recurrent mRCC who underwent nephrectomy were eligible
for this study. Autologous tumor samples were obtained by surgery under aseptic conditions and used for
preparing autologous tumor lysate. About 4 weeks after surgery, leukapheresis was performed to isolate peripheral
blood mononuclear cells (PBMCs). DCs were generated from adherent PBMCs in the presence of recombinant
human granulocyte macrophage colony-stimulating factor (GM-CSF) (500 IU/ml) and recombinant human IL-4
(500 IU/ml). Autologous tumor lysate was loaded into mature DC by electroporation. Eight patients were enrolled in
the study and received sunitinib at a dose of 50 mg p.o. daily for 28 days followed by 14 days of rest. Tumor
lysate-loaded DCs were administered subcutaneously every two weeks, with concomitant sunitinib.
Results: No severe adverse events related to vaccination were observed. Sunitinib decreased the frequencies of
MDSCs in peripheral blood of 5 patients and of Tregs in 3. Tumor lysate-reactive CD4 or CD8 T cell responses were
observed in 5 patients, 4 of whom showed decreased frequencies of Tregs and/or MDSCs. The remaining 3 patients
who failed to develop tumor-reactive T cell responses had high levels of IL-8 in their sera and did not show
consistent reductions in MDSCs and Tregs.
Conclusions: DC-based immunotherapy combined with sunitinib is safe and feasible for patients with mRCC.
Trial registration: UMIN000002136
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Renal cell carcinoma (RCC) accounts for 2–3% of all
adult cancers. Approximately 20–30% of patients present
with metastatic disease. Although surgery is the primary
curative therapy for localized RCC, the prognosis for pa-
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article, unless otherwise stated.year survival rate of <10% [1,2]. Since the first receptor
tyrosine kinase inhibitor (TKI) sorafenib was approved
for the treatment of cytokine-refractory metastatic RCC
(mRCC), many agents have become available for the
treatment of this disease. However, many tumors acquire
resistance to these agents by mutating the target genes or
activating other pathways that bypass the site of inhibition.
This occurs rapidly, often within several months [3].
Therefore, development of other modalities such as im-
munotherapy is still needed for the treatment of mRCC.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Matsushita et al. Journal for ImmunoTherapy of Cancer 2014, 2:30 Page 2 of 10
http://www.immunotherapyofcancer.org/content/2/1/30RCC appears to be one of the most immune-sensitive
cancers. This has encouraged the use of immunomodulat-
ing treatments such as cytokine-based therapy using IL-2
and/or interferon-α (IFN-α) [4,5]. Nonetheless, nephrec-
tomy is still recommended for patients with mRCC [6],
because cytoreductive therapy was shown to provide over-
all survival benefit in patients treated with IFN-α [7]. Al-
though it is still controversial whether cytoreductive
therapy also contributes to the efficacy of TKIs [8], neph-
rectomy reduces the tumor burden, alleviates symptoms
and allows more information on histology to be acquired.
In addition, we can utilize the resected tumor as a source
of autologous materials, such as tumor lysates, for the
production of autologous tumor vaccines. It has been re-
ported that adjuvant treatment with autologous tumor lys-
ate vaccine resulted in a significantly improved overall
survival in pT3 stage RCC patients [9]. Antigen-specific
vaccination with dendritic cells (DCs) has also been con-
ducted, but with only limited success so far [10-15], pos-
sibly due to functionally-defective T cell responses in the
tumor microenvironment.
It is well accepted that the tumor microenvironment im-
poses different degrees of immunosuppression allowing the
tumor to evade immune responses [16]. These include the
delivery of negative costimulatory signals to T cells (via PD-
L1, B7-H4) and production of immunosuppressive factors
(eg. IL-10, TGF-β, IDO and others). Recently, promising
immunotherapeutic strategies have emerged from our un-
derstanding of immunoinhibitory pathways termed “im-
mune checkpoints”, which are crucial for maintaining self-
tolerance and modulating the duration and magnitude of
physiological immune responses. Tumors utilize such im-
mune checkpoints as a resistance mechanism to escape
anti-tumor immune responses [17]. Hence, immune check-
point blockade is a promising approach to activating antitu-
mor immunity. The antibodies that block CTLA-4- and
PD-1-dependent interactions have been successfully applied
for the treatment of mRCC [18-21].
In addition, different regulatory cell populations, such
as MDSCs or Tregs, are involved in this process. The ac-
cumulation of MDSCs as well as the suppression of T-
cell function in mRCC patients has been reported
[22,23]. TKIs such as sunitinib and sorafenib were ap-
proved some time ago and are now the mainstay for the
treatment of mRCC [24-26]. In addition to its anti-
angiogenic effects, sunitinib has been demonstrated to
modulate immunosuppressive MDSCs in human [27]
and mouse [28]. It has also been reported that sunitinib
reverses type-1 immune suppression and decreases
Tregs in renal cell carcinoma patients [29]. Furthermore,
sunitinib, unlike sorafenib, does not inhibit specific T
cell responses [30]. Therefore, sunitinib appears to be a
promising molecular target drug for combination ther-
apy together with cancer vaccines for mRCC.Here, we report the results of a clinical trial in which
we evaluated the safety and feasibility of DC-based vac-
cination combined with sunitinib for mRCC patients
and tested whether sunitinib enhances immune re-
sponses by reducing immunosuppressive cells.
Results
Patients
Eight patients (5 men and 3 women) with a median age of
68 yr (range, 55–75) were enrolled in this study (Table 1).
Two patients were categorized into the MSKCC poor risk
group and the other six as having an intermediate risk.
One patient (#1808) had unclassified RCC, while the other
seven had clear cell RCC. Two patients, #1802 and #1803,
received sunitinib or IFN-α and radiation for bone metas-
tasis, respectively, before surgery.
DC Vaccine combined with sunitinib
DCs were successfully generated from all 8 patients
(Table 2). Final concentrations of tumor lysate per 107
DCs ranged from 0.44 to 1.33 mg (mean value, 0.90 mg).
Flow cytometric analysis of the harvested tumor lysate-
loaded DCs revealed a phenotype characteristic of ma-
ture DCs with high expression of CD40, CD80, CD83,
CD86, HLA-ABC, HLA-DR, and CCR7 (Figure 1 and
Table 3). While there were some differences in the fluor-
escent intensities of these molecules among patients’
DCs (Additional file 1), the phenotype of these DCs
were quite comparable. None of the DC preparations
was microbially contaminated. Each patient was given
1×107 DCs at each time point, with the exception of one
patient (#1823) who received 0.5×107 DCs (Table 2). Pa-
tients received 6 vaccinations and sunitinib at a dose of
50 mg p.o. daily for 28 days followed by 14 days of rest,
according to the schedule (Additional file 2). Vaccination
was well-tolerated and no severe vaccination-related tox-
icity or autoimmune manifestations were observed in
any patient.
Frequencies of MDSCs and Tregs in peripheral blood
MDSCs in peripheral blood were evaluated by two criteria
(percent of CD14−CD15+ or CD33+HLA-DR− cells within
the Dye780−CD45+ population) (Additional file 3). In indi-
vidual patients, decreased percentages of MDSCs were ob-
served in 5 of the 8 patients (#1802, #1803, #1806, #1814,
and #1823) by both criteria (Figure 2A and Table 4) com-
pared to pretreatment baseline. No marked changes were
observed in patients #1808, #1812 and #1817. Sunitinib
significantly reduced the average percentage of CD14−
CD15+ MDSCs in 8 patients from 0.62 ± 1.20% (mean ±
SD) at the baseline to 0.083 ± 0.17% at the 6th DC injec-
tion (p = 0.0039, Wilcoxon signed-rank test); the average
percentage of CD33+HLA-DR− MDSCs in 8 patients did
not change (2.57 ± 2.86% at the baseline and 3.17 ± 6.73%
Table 1 Patients’ characteristics
Patient ID Age/Sex Stage Meta site MSKCC Histology Grade Prior treatment
1802 72/F pT3aN2M1 Lung, LN Poor Clear cell 2 > 3 Sunitinib
1803 72/M pT3bN0M1 Liver, lung, bone Poor Clear cell 3 > 2 IFN-α, radiation
1806 72/F pT4N1M1 Lung, LN Intermediate Clear cell 3 no
1808 75/M pT3aN2M1 Lung, LN, bone Intermediate Unclassified 3 no
1812 61/M pT1bN1M1 LN Intermediate Clear cell 2 > 1> > 3 no
1814 55/M pT3aN0M1 Lung Intermediate Clear cell 2 no
1817 64/F pT3bN1M1 Lung, LN, bone Intermediate Clear cell 3 > 2 no
1823 57/M pT1N0M1 Lung, pleura Intermediate Clear cell 2 > 3 no
MSKCC, Memorial Sloan Kettering Cancer Center risk criteria; LN, lymph node.
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test). For Tregs, the percentages of CD25+Foxp3+ cells
within the Dye450−CD3+CD4+ population (Additional file 3)
were found to be decreased relative to the baseline in
patients #1802, #1803 and #1814, but not in patients
#1806, #1808, #1812, #1817 and #1823 (Figure 2B).
However, there was no statistical difference (p = 0.273,
Wilcoxon signed-rank test).
DTH reactions and tumor-reactive T cell responses
DTH testing was performed in all 8 patients to detect
tumor lysate-reactive responses. Three patients (#1802,
#1814 and #1823) had positive DTH reactions (Table 4).
Tumor lysate-reactive CD4+ and CD8+ T cell responses
in all patients were further investigated in vitro using
the IFN-γ secretion assay at different time points after
vaccination. Data from an individual patient #1802 are
shown in Additional file 3. Before vaccination, the per-
centage of CD8+ IFN-γ+ T cells after simulation with
EP-DCs or unloaded DCs was essentially identical
(1.6%-vs-1.4%, respectively). However, after vaccination,
a higher percentage of CD8+ IFN-γ+ T cells was ob-
served on stimulation with EP-DCs (2.9%) than with
unloaded DCs (1.5%). Similarly, a higher percentage of
CD4+ IFN-γ+ T cells was observed on stimulation with
EP-DCs (4.5%) than with unloaded DCs (3.0%). These T
cell responses fluctuated during the course of treatment
and no statistically significant difference in the increaseTable 2 Quality and quantity of tumor lysate-loaded DCs
Patient ID Tumor lysate used for EP (mg) DCs used for EP (x107) T
1802 15 29.5 0
1803 15 18.3 0
1806 20 17.1 1
1808 7 16.0 0
1812 20 20.1 1
1814 20 21.5 0
1817 20 20.0 1
1823 20 15.0 1
EP, electroporation.of IFN-γ+ T cells after vaccination was detected. Figure 2C
shows the percentage of tumor lysate-reactive IFN-γ+ cells
(both CD4+ as well as CD8+ T cells) for all 8 patients.
When the percentages at any point after vaccination are
elevated 3-fold higher than those at the baseline (mean
value of the percentages at days 0 and 14), the tumor-
reactive T cell responses are considered to be positive. By
this criteria, the induction of tumor lysate-reactive CD4+
T cell responses were detected in patients #1802, #1803,
#1814 and #1823; patients #1802, #1812, #1814 and #1823
had tumor-reactive CD8+ T cell responses (Table 4). The
T cell responses were detected even at the time of registra-
tion in Patients #1808 and 1812.Concentration of IL-8 in the sera
To search for biomarkers predicting responsiveness to
combination therapy with sunitinib and DC-based im-
munotherapy, we analyzed concentrations of IFN-γ, IL-
1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p70, TNF-α,
and TNF-β in sera from the 8 patients before and dur-
ing treatment. With the exception of IL-8, which was
present at different levels in all patients, serum cyto-
kines were barely detectable. Patients #1806, #1808,
#1817 and #1823 had greatly elevated levels of >60 pg/
ml IL-8 during treatment (Figure 2D and Table 4),
whereas patients #1802, #1803, #1812, and #1814 had




















Figure 1 Surface phenotype of DCs; specific mAb staining (red) and isotype control mAb staining (blue).
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The follow-up period ranged from 100 to 1140 days
(Table 4). Except for one patient who died of a brain
hemorrhage due to hypertension, patients remained alive
during the trial with a median overall survival (OS) of
346 days and median progression-free survival (PFS) of
164 days. One patient achieved a complete response (CR),
another patient had a partial response (PR), 3 had stable
disease (SD) and 2 had progressive disease (PD) according
to the RECIST criteria (Table 4). Patient #1814 who
achieved the CR was one of three patients who had devel-
oped DTH, as well as CD4+ and CD8+ T cell responses. In
this patient, the percentages of both MDSCs and Tregs
decreased during treatment. In the CT scan, the size of
the mass in the left lung decreased from 17.9 mm to
8.2 mm in diameter after 6 immunizations and had disap-
peared after 10 (Additional file 4). The other patient who
had a DTH reaction, #1802, also had CD4+ and CD8+ T
cell responses, as well as decreased MDSCs and Tregs,
and low IL-8. She manifested SD in spite of multiple
tumor metastases in the lung (Additional file 4). Her qual-
ity of life was markedly improved by a reduction of the
pleural effusion (Additional file 4). As shown in Additional
file 4, the tumor volume was decreased and pleural effu-
sion was reduced in patient #1823, who develop alsoTable 3 The surface phenotype of DCs
Patient ID % Expression
CD14 CD1a HLA-ABC HLA-DR
1802 7.8 51.6 98.7 99.7
1803 1.4 79.6 99.2 99.9
1806 1.5 36.3 99.8 99.8
1808 5.2 53.3 98.8 99.5
1812 0.6 83 99.9 99.7
1814 0.6 66.5 99.4 99.4
1817 1.4 34.7 99.7 98.3
1823 0.8 50.4 99.7 99.6positive DTH, CD4+ and CD8+ T cell responses (Table 4).
Patient #1812 was defined as PD when target lesion,
supraclavicular lymph node metastasis, was enlarged by
30.3% in size. Therefore, he received surgery to resect the
metastatic lymph node and no recurrence was observed
with no further treatment.
Safety
The most common adverse events were hand-foot syn-
drome, stomatitis, peripheral edema and other skin dis-
orders (Table 5). Sunitinib-related severe adverse events
were hypertension and hematological and laboratory ab-
normalities. They were managed with interruption of su-
nitinib and were reversible in most cases, except for a
fatal hypertensive intracranial hemorrhage in patient
#1806 who had no brain metastasis. No severe adverse
events related to DC therapy were observed.
Discussion
Here we report a clinical trial of DC-based immunotherapy
combined with sunitinib in mRCC patients. We evaluated
the safety and feasibility of this approach. In the course of
treatment, one patient developed cerebral hemorrhage due
to hypertension. However, no severe vaccination-related
toxicity or autoimmunity was observed in any of the 8CCR7 CD40 CD80 CD83 CD86
10.6 99.9 96.4 60.1 96.3
38.7 99.4 99.1 94.1 99.5
49.1 99.9 98.5 90.8 99
43.1 99.4 96.7 75.6 98.7
10.3 99.8 99.2 87.4 97.9
58.3 99.6 98.7 91.5 99.2
50.3 99.8 96.7 61.8 98
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Figure 2 Immunomonitoring. A. Percentages of MDSCs by two criteria. B. Percentages of Tregs. C. Changes of tumor-reactive IFN-γ+ cells (% of
CD4+ or CD8+ T cells). Assay was performed as described in Methods section. D. The concentration of IL-8 in sera measured by a
cytofluorometry-based ELISA system at different time points during treatment of the 8 patients.
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ipheral blood MDSCs and/or Tregs. Vaccination with
tumor lysate-loaded DCs induced tumor-reactive CD4+
and/or CD8+ T cell responses. The treatment showed some
clinical benefits in patients possibly linked to successful
control of immunosuppressive cells and induction of T cell
responses. This was particularly notable in patient #1814
where lung metastases disappeared. However, there is a
possibility that these clinical responses are solely due to su-
nitinib rather than vaccine-induced immune response,
since the DC was given concurrently with sunitinib which
is an active drug for the treatment of RCC.
Consistent with previous reports [27,29], we observed re-
duced percentages of MDSCs during sunitinib treatment,
but only in 5 of 8 patients (Figure 2A and Table 4). Of these
5, 4 developed increased tumor-reactive T cell responses.
However, the very low number of patients included in thisstudy and the fluctuations in magnitude of T cell responses
during the course of treatment make it difficult to conclude
the relationship between MDSC and T cell responses. Re-
garding mechanisms underlying the modulation of MDSCs
by sunitinib, it has been shown that this agent inhibits
STAT3 signaling. This induces apoptosis in murine
MDSCs, where STAT3 is a critical factor responsible for
their expansion [31,32]. On the other hand, GM-CSF accu-
mulating in the tumor expands MDSCs to promote
sunitinib-resistance due to preferential STAT5 activation,
which cannot be suppressed by sunitinib [33]. Thus, to
understand the different sensitivity of MDSCs to sunitinib
in different mRCC patients, the STAT3 or STAT5 activa-
tion status in the MDSCs and expression of cytokines such
as GM-CSF in the tumor would need to be investigated.
A decreased percentage of Tregs after sunitinib treat-
ment was also observed, although only in 3 of the 8
Table 4 Immune responses and clinical outcomes in 8 patients
ID No. DC
injection











1802 6 + + + decreased decreased low −25.4 SD 173 339 Dead
1803 6 - + - decreased decreased low 0 SD 200 353 Dead
1806 6 - - - decreased no
change
high −18.4 N.A.¶ 100 100 Dead
1808 6 - - - no
change
increased high −5.4 SD 155 193 Dead




low 30.3 PD# 101 1140|| Alive
1814 12 + + + decreased decreased low −100 CR 347 1127|| Alive
1817 6 - - - no
change
increased high −27.8 PD** 88 206 Dead
1823 12 + + + decreased no
change
high −35.3 PR 342|| 342|| Alive
PFS, progression free survival; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
*Compared to the baseline.
†High or low is defined as more or less than 60 pg/ml in sera.
‡4wks after last injection.
§From the registration (days).
¶Withdrawn from the study by sudden hypertensive cerebral hemorrhage.
||A censored case due to the termination of the study.
#After surgical removal of target lesion (LN metastasis), no recurrence was observed.
**Though target lesion became smaller, accumulation of pleural effusion was increased.
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lying regulation of Tregs by sunitinib remains unclear. It
has been proposed that the reduction of Tregs by suniti-
nib may be an indirect effect of the downregulation of
MDSCs and/or increases in IFN-γ production [27]. In our
case, reduced frequencies of Tregs were observed in 3 of
the 5 patients who did show reduced MDSCs. No reduc-
tion of Tregs was seen in a further 3 of 3 patients in whom
there was no reduction of MDSCs. Nevertheless, the num-
ber of patients was too small to lead to any conclusion.
To identify biomarkers for predicting outcome of com-
bination sunitinib and DC-based immunotherapy, we
tested a wide range of cytokines (IFN-γ, IL-1β, IL-2, IL-
4, IL-5, IL-6, IL-8, IL-10, IL-12 p70, TNF-α, and TNF-β)
in sera from patients before and during treatment. We
found IL-8 in all patients, with 4 having highly elevated
levels (>60 pg/ml) during treatment. IL-8 is a member of
the CXC family of chemokines and is a potent proangio-
genic factor [34]. Renal cell carcinoma has been shown
to produce IL-8, and IL-8 expression is known to cause
mRCC resistance to sunitinib [35,36]. IL-8 angiogenic
signaling is thought to functionally compensate for
the inhibition of VEGF/VEGFR-mediated angiogenesis.
Further, the secretion of IL-8 from cancer cells may have
a variety of effects on the tumor microenvironment, be-
cause the IL-8 receptors CXCR1 and CXCR2 are
expressed on cancer cells, endothelial cells, neutrophils
and tumor-associated macrophages. It has been shown
that production of IL-8 by tumors induces Treg migra-
tion into tumors [36]. IL-8 produced by tumor cells mayalso recruit MDSCs into tumor sites. Therefore, high IL-
8 expression may contribute to shaping the immunosup-
pressive environment in the tumor and inhibiting
tumor-reactive T cell responses. In this study, no reduc-
tion of IL-8 was achieved by sunitinib (Figure 2D).
Therefore, targeting IL-8 signaling may be required for
improving this cancer vaccine.
Cancer immunotherapy based on the regulation of im-
munosuppressive cells, soluble factors, and signaling
pathways are now considered essential element of the
treatment of cancer [37]. Similar effects are also achieved
by molecular targeted therapy, which primarily aims to in-
hibit molecular pathways that are crucial for tumor cell
growth and survival. Importantly, such small molecule in-
hibitors may also modulate the immune system, which
raises the possibility that targeted therapy might be effect-
ively combined with immunotherapy to improve clinical
outcomes [38]. This may indeed be the case in our small
pilot study. A reduction of immunosuppressive cells by
sunitinib likely contributed to stimulating anti-tumor im-
mune responses induced by tumor lysate-loaded DC
vaccines.
Initially 15 patients were planned to be included in this
study; we terminate the study with 8 patients reproted
here, because other TKIs, pazopanib and axitinib, and
mTOR inhibitors, temsirolimus and everolimus, are now
available for the RCC treatment in addition to sunitinib
and sorafenib. A new pilot study is currently underway to
determine the better combination of these molecular tar-
get drugs with DC-based immunotherapy. Though our
Table 5 Adverse Events and Laboratory abnormalities
Grade
Adverse Events, Regardless of Causality All 1 2 3 4 5
General disorders
Fatigue 2 2








Respiratory, thoracic and mediastinal disorders
Cough 1 1
Musculoskeletal and connective tissue disorders
Back pain 3 1 2
Metabolism and nutrition disorders
Hypothyroidism 4 4
Skin and subcutaneous tissue disorders
Hand-foot syndrome 8 2 6
Stomatitis 4 2 2
Peripheral Edema 4 3 1
Anal diseases 3 3





Hypertension 3 1 1 1*
Hematological and other laboratory abnormalities





Increased creatinine 2 2
*Intracranial hemorrhage.
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tion study and sample size was only 8 patients, our results
support the notion that immunotargeted therapy repre-
sents an appropriate future direction for developing suc-
cessful treatment of mRCC.
Conclusions
This pilot study of DC-based therapy together with suniti-
nib for mRCC patients has documented the safety andfeasibility of this approach. The reduction of both MDSCs
and Tregs was achieved by sunitinib in patients whose
serum IL-8 levels were not excessive. Autologous tumor
lysate-loaded DCs in combination with sunitinib induced
both CD4+ and CD8+ T cell responses in mRCC patients.
Methods
Patient selection
A pilot study of DC-based immunotherapy combined with
sunitinib in mRCC patients was conducted. The primary
endpoints were the safety and feasibility of this approach;
the secondary endpoints were to obtain immunological
proof of concept and preliminary data for anti-tumor ef-
fect, overall survival (OS) and progression-free survival
(PFS). Patients aged ≥20 years with advanced or recurrent
mRCC who underwent nephrectomy were eligible for this
clinical study of DC therapy combined with sunitinib. To
be included, patients had to have an Eastern Cooperative
Oncology Group performance status (PS) of 0, 1 or 2, nor-
mal kidney, liver, and bone marrow function, and at least
1 measurable cancer lesion assessed by computed tomog-
raphy. Patients positive for anti-adult T-cell leukemia-
associated antigen or anti-human immunodeficiency virus
antibody, other primary cancers, uncontrolled infection,
active enterocolitis, severe heart disease, severe drug al-
lergy, cryoglobulinemia, or autoimmune disease, were ex-
cluded from the study. Those receiving systemic steroid
therapy, who were pregnant or lactating, or who had brain
metastasis and hypertension were also excluded. The
research protocol was approved by the Ethical Committee
of our institution and was registered at the University Hos-
pital Medical Information Network Clinical Trials Registry
(UMIN-CTR) (Unique trial number: UMIN000002136) on
July 2, 2009. Written informed consent was obtained from
each patient before they entered the study. The study was
performed in accordance with the Declaration of Helsinki.
Generation of DCs
About 4 weeks after surgery, patients underwent leuka-
pheresis to isolate peripheral blood mononuclear cells
(PBMCs) using a Fresenius AS.TEC204 with the C4Y
white blood cell set. Approximately 5 ×109 PBMCs from
each patient were allowed to adhere to tissue culture flasks
in AIM-V medium (Invitrogen, Carlsbad, CA) at 37°C.
After one hour, nonadherent cells were removed by
washing with warm medium. To generate immature
DCs, adherent PBMCs were cultured in AIM-V for
5 days in the presence of recombinant human granulo-
cyte macrophage colony-stimulating factor (GM-CSF)
(500 IU/ml; Berlex Laboratories, Montville, NJ) and re-
combinant human IL-4 (500 IU/ml; CellGenix Technologie
Transfer GmbH, Freiburg, Germany). Immature DCs were
then matured by adding GM-CSF (250 IU/ml), recombinant
human IL-4 (250 IU/ml), tumor necrosis factor (TNF-α)
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taglandin E2 (PGE2) (1 μg/ml; Sigma, St. Louis, MO) and
zoledronate (5 μM; Novartis, Basel, Switzerland) for a fur-
ther 2 days [39].
Preparation of tumor lysates and electroloading of
dendritic cells
Autologous tumor samples were obtained by surgery
under aseptic conditions. Tumor tissues were minced with
a scalpel in phosphate-buffered saline (PBS). The samples
were then lysed by six freezing and thawing cycles, soni-
cated and centrifuged to produce tumor lysate. Finally the
supernatant was filtered using 0.22-μm pore-size filters.
The quantitation of total protein was performed using
BCA Protein Assay Kit (Pierece Biotechnology, Rockford.
IL, USA) according to the manufacturer’s instruction. Col-
orimetric changes were detected by VersaMax microplate
reader (Molecular Device Japan, Tokyo, JAPAN) at the
wavelength of 562 nm with Softmax Pro software (Mo-
lecular Device Japan). Autologous tumor lysate was loaded
into mature DCs using a MaxCyte GT electroporation-
based system (MaxCyte Inc, Gaithersburg, MD) according
to the manufacturer’s instructions [40]. Tumor lysate-
electroporated DCs, designated EP-DCs, were cryopre-
served with 1 ml of autologous serum containing 10%
DMSO and stored in liquid N2 until use.
Immunization schedule
After leukapheresis, patients received sunitinib at a dose
of 50 mg p.o. daily for 28 days followed by 14 days of
rest. Two weeks after leukapheresis, patients received
1x107 EP-DCs subcutaneously in the deltoid region; DC
injection was repeated biweekly six times in total, ex-
tended to 12 for one long-surviving patient. For immu-
nomonitoring, peripheral blood was drawn before DC
therapy, at each treatment time point and 4 weeks after
the last treatment. PBMCs were isolated by density
gradient centrifugation using Lymphoprep (Axis-Shield,
Oslo, Norway) and stored in liquid N2 until use. Ad-
verse events were graded according to National Cancer
Institute-Common Terminology Criteria for Adverse
Events version 4.0. Clinical responses were assessed by
computed tomography and classified as complete re-
sponse (CR), partial response (PR), stable disease (SD),
or progressive disease (PD) according to the Response
Evaluation Criteria in Solid Tumors (RECIST) criteria,
version 1.1 [41].
IFN-γ secretion assay
PBMCs (1×106) from each time point and EP-DCs
(1×105) were thawed and resuspended in AIM-V medium
supplemented with 10% heat-inactivated pooled human
serum (complete medium), and co-cultured in a 24-well
plate at 37°C in a 5% CO2 atmosphere for 2 days.Recombinant human IL-2 (Chiron, Emeryville, CA) was
then added every 2–3 days to a final concentration of
50 IU/ml for another 12 days. The cultured PBMCs were
harvested and used as responder cells, as described
below. The IFN-γ secretion assay was carried out ac-
cording to the manufacturer’s protocol (Miltenyi Biotec,
Bergisch Gladbach, Germany) [42]. Briefly, 1 × 106 re-
sponder cells were stimulated with 1 × 105 EP-DCs or
mature DCs without electroporation (unloaded DCs) in
complete medium for 4 hr at 37°C in a 5% CO2 atmos-
phere. The cells were then washed and suspended in
100 μl of cold PBS, and treated with a mouse anti-IFN-γ
antibody (IFN-γ catch reagent) (2 μl) for 5 min on ice.
The cells were then diluted in complete medium (1 ml)
and placed on a slowly rotating device (Miltenyi Biotec)
to allow IFN-γ secretion at 37°C in a 5% CO2 atmos-
phere. After incubation for 45 min, the cells were
washed with cold PBS and treated with Fixable viability
dye eFluor 450 (eBioscience, San Diego, CA), PE-labeled
anti-IFN-γ (detection reagent), Alexa Fluor 647-labeled
anti-human CD3 (Biolegend, San Diego, CA), PC5-
labeled anti-human CD8 (Beckman Coulter, Fullerton,
CA), and PECy7-labeled anti-human CD4 (Biolegend)
mAbs. After incubation for 10 min at 4°C, the cells were
washed and analyzed on a Gallios Flow Cytometer
(Beckman Coulter).
Tregs and MDSCs
Analysis of Treg percentages in patient PBMC was car-
ried out on thawed samples. Cells were stained in
fluorescence-activated cell sorting (FACS) buffer (1×
PBS with 2% heat-inactivated fetal bovine serum and
0.02% sodium azide). Nonspecific antibody binding was
blocked by pretreatment with Clear Back (Human Fc re-
ceptor blocking reagent, MBL, Nagoya, Japan). Cells
were stained with Dye450, Alexa Fluor 647-labeled anti-
CD3, Alexa Fluor 488-labeled Foxp3, PE-Cy5-labeled
CD4, and PE-labeled CD25 Abs according to the in-
structions for use of the Human Treg Flow Kit (Biole-
gend). MDSCs were also analyzed by FACS on thawed
patient PBMC stained with Dye780, ECD-labeled CD14
(Beckman Coulter), FITC-labeled CD15 (Biolegend), PE-
Cy5-labeled CD33 (Biolegend), and PE-labeled HLA-DR
(BD Biosciences) Abs for 30 min at 4°C. Cells were
washed in buffer and then fixed in 1% paraformaldehyde
and analyzed by flow cytometry.
Delayed-type hypersensitivity (DTH)
EP-DCs or unloaded DCs were injected intradermally
into different forearms. DTH reactions were evaluated
24 and 48 hours after the 6th injection of DCs and con-
sidered to be positive when a skin reaction (>10 mm
diameter of erythema) was triggered by EP-DCs but not
unloaded DCs.
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Amounts of IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10,
IL-12 p70, TNF-α, and TNF-β in patients′ sera were quan-
tified by a cytofluorometry-based ELISA system (Flowcyto-
mix, Bender Medsystems GmbH, Austria). Standard curves
for each cytokine were generated using the reference cyto-
kine concentrations supplied by the manufacturer. Cyto-
kines in sera from patients at different time points were
estimated according to the manufacturer’s instructions.
Raw data of the FC bead assay were analyzed by FlowCyto-
mixPro2.3 software.
Statistical analysis
The statistical analyses of immunological parameters and
prognostic factors (PFS or OS) were performed using
Wilcoxon signed-rank test and Kaplan-Meier method, re-
spectively, with JMP software, version 9.0.3 (SAS Institute
Inc., Cary, NC, USA).
Additional files
Additional file 1: The mean fluorescent intensity (MFI) of the
surface expression of immunological molecules. Tabular data.
Additional file 2: Schedule for DC vaccination combined with
sunitinib in this clinical trial. Supplementary figure.
Additional file 3: Data from an individual patient. Supplementary figure.
Additional file 4: Computed tomography (CT) images. Supplementary
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